Tampere University Hospital Department of Oncology
Welcome,         Profile    Billing    Logout  
 0 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tanner, Minna
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NCT04796324 / 2020-004610-35: Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Recruiting
2
60
Europe
Ixabepilone Injection
Allarity Therapeutics, Allarity Therapeutics
Metastatic Breast Cancer
10/24
11/25
FINPROVE, NCT05159245 / 2021-000689-14: The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

Recruiting
2
250
Europe
Alectinib, Alecensa, Cobimetinib, Cotellic, Vismodegib, Erivedge, Trastuzumab+Pertuzumab, Phesgo, Entrectinib, Rozlytrek, Atezolizumab, Tecentriq, Vemurafenib, Zelboraf, Regorafenib, Stivarga, Apalutamide, Erleada, Abemaciclib, Verzenio, Tepotinib, Tepmetko, Dabrafenib, Tafinlar, Trametinib, Mekinist, Dabrafenib+Trametinib, Tafinlanr+Mekinist, Pemigatinib, Pemazyre
Helsinki University Central Hospital, Helsinki University Hospital
Advanced Cancer, Solid Tumor, Haematological Malignancy
11/26
11/26
Iivanainen, Sanna
FINPROVE, NCT05159245 / 2021-000689-14: The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

Recruiting
2
250
Europe
Alectinib, Alecensa, Cobimetinib, Cotellic, Vismodegib, Erivedge, Trastuzumab+Pertuzumab, Phesgo, Entrectinib, Rozlytrek, Atezolizumab, Tecentriq, Vemurafenib, Zelboraf, Regorafenib, Stivarga, Apalutamide, Erleada, Abemaciclib, Verzenio, Tepotinib, Tepmetko, Dabrafenib, Tafinlar, Trametinib, Mekinist, Dabrafenib+Trametinib, Tafinlanr+Mekinist, Pemigatinib, Pemazyre
Helsinki University Central Hospital, Helsinki University Hospital
Advanced Cancer, Solid Tumor, Haematological Malignancy
11/26
11/26
MATINS, NCT03733990 / 2018-002732-24: A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients

Completed
1/2
216
Europe, US
FP-1305 (bexmarilimab), bexmarilimab
Faron Pharmaceuticals Ltd
Cancer
09/23
10/23
NCT04081558: Electronic Symptom Follow-up of Cancer Patients

Recruiting
N/A
100
Europe
Electronic patient reported outcomes tool
Oulu University Hospital
Cancer
06/21
09/21
NCT05630950: LDCT-SC-FI Low-dose CT Screening for Lung Cancer

Active, not recruiting
N/A
200
Europe
Smoking cessation mobile application, Written material for smoking cessation
Oulu University Hospital
Lung Cancer Screening
12/24
12/25

Download Options